Claudio Liguori

TL;DR: The results demonstrate that, in AD, increased cerebrospinal fluid orexin levels are related to a parallel sleep deterioration, which appears to be associated with cognitive decline.

TL;DR: It is hypothesized that OSA reducing sleep quality and producing intermittent hypoxia lowers CSF Aβ42 levels, increases CSF lactate levels, and alters cognitive performances in SCI patients, thus inducing early AD clinical and neuropathological biomarkers changes.

TL;DR: Patients with SARS-CoV2 infection frequently present with subjective neurological symptoms (sNS), and laboratory findings correlated with the occurrence of hyposmia, dysgeusia, headache, daytime sleepiness, and depression.

TL;DR: A dynamic relationship between neuronal energy metabolism, τ proteins and cognitive decline in AD is suggested and the clinical potential of assessing CSF lactate levels in patients with AD is proposed to better define the neuronal brain metabolism damage.

TL;DR: REM sleep disruption and sleep fragmentation are related to higher CSF-orexin levels in patients with MCI due to AD, thus suggesting that the orexin system may be involved even in the earliest stages of AD, resulting in prolonged sleep latency, reduced sleep efficiency, and REM sleep impairment.